{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=16", "query": { "intervention": "Radiotherapy followed by chemotherapy", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 887, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T01:26:47.134Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06833502", "title": "Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Node-positive Breast Cancer" ], "interventions": [ { "name": "CT Scan", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-02-24", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06833502" }, { "nct_id": "NCT00002598", "title": "Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 30, "start_date": "1994-06", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002598" }, { "nct_id": "NCT07725406", "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed or Refractory Multiple Myeloma (MM)" ], "interventions": [ { "name": "Lymphodepleting chemotherapy: Cyclophosphamide", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy: Bendamustine", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy: Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "OTHER" }, { "name": "Axicabtagene Ciloleucel", "type": "OTHER" }, { "name": "Ciltacabtagene Autoleucel", "type": "OTHER" }, { "name": "Low-Dose Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-08-01", "completion_date": "2033-08-31", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07725406" }, { "nct_id": "NCT00019071", "title": "Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "cladribine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1995-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019071" }, { "nct_id": "NCT00358657", "title": "Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunodeficiency Syndrome", "Severe Aplastic Anemia", "Genetic Disorder" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 14, "start_date": "2006-05-24", "completion_date": "2019-05-25", "has_results": true, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 3, "location_summary": "Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358657" }, { "nct_id": "NCT02318095", "title": "Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Resectable Pancreatic Cancers" ], "interventions": [ { "name": "Gemcitabine/nab-Paclitaxel", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Sugical resection", "type": "OTHER" }, { "name": "Adjuvant chemotheapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-02-17", "completion_date": "2022-11-14", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02318095" }, { "nct_id": "NCT03490292", "title": "Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Resectable Esophageal Cancer", "GastroEsophageal Cancer" ], "interventions": [ { "name": "Avelumab combined with Chemoradiation", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG", "RADIATION" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-05-29", "completion_date": "2023-07-12", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03490292" }, { "nct_id": "NCT01847326", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Tongue Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "hyperfractionated radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-03-26", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01847326" }, { "nct_id": "NCT02722668", "title": "UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia/Lymphoma", "Burkitt's Lymphoma", "Natural Killer Cell Malignancies", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Large-cell Lymphoma", "Hodgkin Lymphoma", "Multiple Myeloma", "Relapsed Chronic Lymphocytic Leukemia", "Relapsed Small Lymphocytic Lymphoma", "Marginal Zone B-cell Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle-cell Lymphoma", "Prolymphocytic Leukemia", "Bone Marrow Failure Syndromes", "Myeloproliferative Neoplasms/Myelofibrosis", "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias", "MRD Positive Leukemia", "Leukemia or MDS in Aplasia", "Relapsed T-Cell Lymphoma", "Relapsed Multiple Myeloma", "Plasma Cell Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "TBI", "type": "RADIATION" }, { "name": "Umbilical cord blood cell infusion", "type": "BIOLOGICAL" }, { "name": "ATG", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 15, "start_date": "2017-05-15", "completion_date": "2024-02-22", "has_results": true, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722668" }, { "nct_id": "NCT01723774", "title": "PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "PD0332991", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Surgery (standard of care)", "type": "PROCEDURE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 84, "start_date": "2013-04-10", "completion_date": "2027-11-07", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T01:26:47.134Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01723774" } ] }